NCT00485836View on ClinicalTrials.gov

A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)

PHASE3CompletedINTERVENTIONAL
Enrollment

392

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

December 31, 2009

Conditions
Macular EdemaRetinal Vein Occlusion
Interventions
DRUG

Sham injection

Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.

DRUG

Ranibizumab injection 0.3 mg

Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.

DRUG

Ranibizumab injection 0.5 mg

Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY